Media.Player

Method To Prevent Biofilm Formation in Various Clinical Settings (Contact Lenses, Wounds, Cystic Fibrosis, Etc.)

技術優勢

This therapy, focused on biofilm prevention or degradation, is particularly applicable for early stage CF in young patients when antimicrobial agents are only partially effective at best.

技術應用

Targeted therapy for preventing or reducing biofilm formation in cystic fibrosis and in other diseases such as infectious kidney stones, cystitis, dental caries, chronic otitis media, bacterial endocarditis, osteomyelitis, wounds (usually burns), and acne.Prevention of microbial biofilm development on orthopedic implants, stents, catheters and other medical devices.An assay to test compounds for their ability to prevent/reduce biofilm formation by assessing the ability of microbial organisms to bind to actin.

詳細技術說明

Our scientists have shown the following in vitro :Biofilm development of P. aeruginosa is enhanced with:the addition of human viable neutrophils and correlates with an increase in the number of necrotic neutrophils.the addition of neutrophils lysates and particularly with monomeric actin (G-actin).Biofilm development of P. aeruginosa is reduced with:the addition of neutrophils lysates depleted of actin microfilaments (F-actin).the addition of compunds that promotes the depolymerization of F-actin, such as gelsolin or charged poly(amino acids).Using a state grant to identify the most effective charged poly (amino acids) at disrupting biofilms and testing such compounds on infected contact lenses, and in animal models of eye and skin infections.

*Abstract

Researchers at National Jewish Health have determined that actin originating from necrotized human neutrophils serve as a biological matrix in the formation of microbial biofilms in the airways of cystic fibrosis (CF) patients. Since biofilm formation allows for the survival of microbial organisms in the airways of CF patients and is also associated with increased morbidity and mortality, targeting actin and/or neutrophils could be the basis for the development of a potential therapy for CF.

*Principal Investigation

Name: Jerry Nick, Associate Professor

Department: Department of Medicine

附加資料

Patent Number: US20080199509A1
Application Number: US200831029A
Inventor: Nick, Jerry A. | Parks, Quinn M.
Priority Date: 15 Feb 2007
Priority Number: US20080199509A1
Application Date: 14 Feb 2008
Publication Date: 21 Aug 2008
IPC Current: A61K000900 | A01N003718 | A01N004348 | A01P000100 | A61K003802 | A61K003816 | A61P003104
US Class: 424423 | 5140011 | 514044R | 514002 | 514012 | 514044
Assignee Applicant: National Jewish Medical and Research Centernver
Title: Methods and Compositions for the Disruption of Biofilms
Usefulness: Methods and Compositions for the Disruption of Biofilms
Summary: For inhibiting or reducing biofilm associated with cystic fibrosis, bacterial keratitis or severe bum or wound (claimed), kidney stones, cystitis, catheter-related infection (kidney, vascular, peritoneal), medical device-related infections, prostatitis, dental caries, chronic otitis media, bronchiectasis, bacterial endocarditis, Legionnaire's disease, orthopedic implant infection, osteomyelitis, acne, and biliary stents.
Novelty: Biofilm formation (e.g. associated with cystic fibrosis, bacterial keratitis or severe bum or wound) is inhibited or reduced by administering charged compound comprising anionic or cationic polyamino acid

主要類別

生物醫學

細分類別

病原

國家/地區

美國